secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001641172-25-003034
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics replaces auditor Marcum LLP with CBIZ CPAs; notes material weaknesses and going concern
--------------------------------------------------------------------------------

- Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.
- Marcum's reports for FY2023 and FY2024 included an explanatory paragraph about substantial doubt on the company's ability to continue as a going concern.
- Company disclosed material weaknesses in internal control over financial reporting for both FY2023 and FY2024, including lack of segregation of duties.
- No disagreements on accounting principles occurred between the company and Marcum during the relevant periods.
- Marcum furnished a letter agreeing with the statements; filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225003034/0001641172-25-003034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225003034/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer